中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 计算技术研究所
  3. 中国科学院计算技术研究所
  4. 中国科学院计算技术研究所期刊论文
  5. 英文
DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations

文献类型：期刊论文

作者Yang, Mei2; Fan, Yanhui3,4; Wu, Zhi-Yong5; Gu, Jin14; Feng, Zhendong3; Zhang, Qiangzu3; Han, Shunhua3,7; Zhang, Zhonghai8; Li, Xu8; Hsueh, Yi-Ching3
刊名EBIOMEDICINE
出版日期2021-07-01
卷号69页码:11
ISSN号2352-3964
关键词HER2-negative breast cancer Germline rare coding mutations Damage assessment of genomic mutations (DAGM) Risk assessment Activity profiles of signalling pathways (APSP) HER2 signalling pathway Immune suppression
DOI10.1016/j.ebiom.2021.103446
英文摘要Background: Breast cancers can be divided into HER2-negative and HER2-positive subtypes according to different status of HER2 gene. Despite extensive studies connecting germline mutations with possible risk of HER2-negative breast cancer, the main category of breast cancer, it remains challenging to obtain accurate risk assessment and to understand the potential underlying mechanisms. Methods: We developed a novel framework named Damage Assessment of Genomic Mutations (DAGM), which projects rare codingmutations and gene expressions into Activity Profiles of Signalling Pathways (APSPs). Findings: We characterized and validated DAGM framework at multiple levels. Based on an input of germline rare coding mutations, we obtained the corresponding APSP spectrum to calculate the APSP risk score, which was capable of distinguish HER2-negative from HER2-positive cases. These findings were validated using breast cancer data from TCGA (AUC = 0.7). DAGM revealed that HER2 signalling pathway was up-regulated in germline of HER2-negative patients, and those with high APSP risk scores had exhibited immune suppression. These findings were validated using RNA sequencing, phosphoproteome analysis, and CyTOF. Moreover, using germline mutations, DAGM could evaluate the risk for HER2-negative breast cancer, not only in women carrying BRCA1/2 mutations, but also in those without known disease-associated mutations. Interpretation: The DAGM can facilitate the screening of subjects at high risk of HER2-negative breast cancer for primary prevention. This study also provides new insights into the potential mechanisms of developing HER2-negative breast cancer. The DAGM has the potential to be applied in the prevention, diagnosis, and treatment of HER2-negative breast cancer. (C) 2021 The Authors. Published by Elsevier B.V.
资助项目National Key Research and Development Program of China[2018YFC0910406] ; National Key Research and Development Program of China[2018AAA0103302] ; National Natural Science Foundation of China[81202076] ; National Natural Science Foundation of China[82072939] ; National Natural Science Foundation of China[81871513] ; Guangzhou Science and Technology Program key projects[2014J2200007] ; Guangzhou Science and Technology Program key projects[202002030236] ; National Key R&D Program of China[2017YFC1309100] ; Shenzhen Science and Technology Planning Project[JCYJ20170817095211560] ; Natural Science Foundation of Guangdong Province[2017A030313882] ; Natural Science Foundation of Guangdong Province[S2013010012048] ; Natural Science Foundation of Guangdong Province[KF2020009] ; RGC General Research Fund[17114519]
WOS研究方向General & Internal Medicine ; Research & Experimental Medicine
语种英语
出版者ELSEVIER
WOS记录号WOS:000684979000017
源URL[http://119.78.100.204/handle/2XEOYT63/17261]  
专题中国科学院计算技术研究所期刊论文_英文
通讯作者Niu, Gang; Wang, Kun
作者单位1.Shenzhen Univ, Inst Microscale Optoelect, Shenzhen, Peoples R China
2.Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Canc Ctr, Dept Breast Canc, Guangzhou, Guangdong, Peoples R China
3.Phil Rivers Technol, Beijing 100095, Peoples R China
4.Phil Rivers Technol, Shenzhen, Peoples R China
5.Shantou Cent Hosp, Diag & Treatment Ctr Breast Dis, Shantou, Guangdong, Peoples R China
6.Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China
7.Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA
8.Chinese Acad Sci, Inst Comp Technol, State Key Lab Comp Architecture, Beijing, Peoples R China
9.Tsinghua Univ, MOE Key Lab Bioinformat, TNLIST, Beijing, Peoples R China
10.Tsinghua Univ, Bioinformat Div, TNLIST, Beijing, Peoples R China
推荐引用方式
GB/T 7714		 Yang, Mei,Fan, Yanhui,Wu, Zhi-Yong,et al. DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations[J]. EBIOMEDICINE,2021,69:11.
APA Yang, Mei.,Fan, Yanhui.,Wu, Zhi-Yong.,Gu, Jin.,Feng, Zhendong.,...&Wang, Kun.(2021).DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations.EBIOMEDICINE,69,11.
MLA Yang, Mei,et al."DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations".EBIOMEDICINE 69(2021):11.

入库方式： OAI收割

来源：计算技术研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。